AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6102409
Drug: Floctafenine 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Floctafenine 1.2 g daily
Trial: 27453081
Drug: Combination (COMB)
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (COMB)
Trial: 23834253
Drug: Synthetic extracellular
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic extracellular matrix protein as an adjunct to standard care
Trial: 17635734
Drug: Combined anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined anticoagulant and antiplatelet therapy
Trial: 22398668
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel
Trial: 12445486
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) infusion (30 microg/30 min)
Trial: 9435411
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rHGH) 0.2 mg/kg.day
Trial: 9435411
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rHGH)
Trial: 8085776
Drug: Diltiazem LP
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem LP 300 mg (morning administration)
Trial: 8085776
Drug: Diltiazem LP
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem LP 300 mg (evening administration)
Trial: 8085776
Drug: Diltiazem LP
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem LP 300 mg (both morning and evening)
Trial: 30511840
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (n = 41, 4 capsules/day, equivalent to 2 g of eicosapentaenoic acid plus docosahexaenoic acid)
Trial: 26447153
Drug: 25(OH)D concentration
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25(OH)D concentration ≥30 ng/mL in former and current smokers
Trial: 21282528
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation (control group) with no extra therapy
Trial: 19411747
Drug: Antidepressant and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant and psychological intervention
Trial: 7857354
Drug: Pidotimod (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pidotimod (400 mg oral bottle daily)
Trial: 1054855
Drug: 0.5% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% chlorhexidine gluconate gel
Trial: 18082830
Drug: Sodium dodecyl
RxNorm normalized name: Sodium dodecyl sulfate
DrugBank: Sodium lauryl sulfate (DB00815)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium dodecyl sulfate polyacrylamide gel electrophoresis with silver staining
Trial: 2979690
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg intravenous)
Trial: 25329159
Drug: n‐3 long‐chain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 long‐chain polyunsaturated fatty acids (n‐3 LCPUFA) 4 g daily for 8 weeks
Trial: 25329159
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (OO) 4 g daily for 8 weeks
Trial: 11256057
Drug: Five structured
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five structured clinical interviews (SCI-PAS, SCI-MOODS, SCI-SHY, SCI-OBS, SCI-ABS) administered along with a diagnostic interview and self-report instruments.
Trial: 9346220
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m2 over 3 hours) with carboplatin (AUC 5)
Trial: 9346220
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m2 over 3 hours) with cisplatin (75 mg/m2)
Trial: 8452174
Drug: Fleroxacin 400
RxNorm normalized name: fleroxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 400 mg orally once daily for 4-21 days
Trial: 8452174
Drug: Amoxicillin/clavulanate potassium
RxNorm normalized name: Amoxicillin/Clavulanate Potassium 250 MG-125 MG Oral Tablet
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate potassium (AMX/CP) 500 mg/125 mg orally three times daily for 4-21 days
Trial: 8888359
Drug: D-amphetamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-amphetamine (0.5 mg/kg)
Trial: 3287703
Drug: Pentoxifylline (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (16 mg/kg/day IV for 3 days, then 400 mg t.i.d. for 28 days)
Trial: 26250486
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (200 μg as tablet for 6 weeks)
Trial: 24558759
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 5.0 mg/kg (group A)
Trial: 24558759
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 7.5 mg/kg (group B)
Trial: 21332932
Drug: Etoricoxib 30
RxNorm normalized name: Etoricoxib 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 30 mg/day
Trial: 23748324
Drug: TiUnite implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TiUnite implants
Trial: 17100744
Drug: Turned implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turned implants
Trial: 15301100
Drug: Liquefacient nitrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquefacient nitrogen cryotherapy with antibiotic eye drops and ointments
Trial: 9329359
Drug: Octreotide (OCT)
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide (OCT) treatment (150-600 micrograms/day for 3-6 months)
Trial: 9329359
Drug: Octreotide (OCT)
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide (OCT) treatment
Trial: 24247476
Drug: Glucagon-like peptide-1
RxNorm normalized name: Glucagon-like peptide-1 (GLP-1) analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon-like peptide-1 (1.5 pmol/kg/min) plus intensive insulin therapy
Trial: 24247476
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline plus intensive insulin therapy
Trial: 20673995
Drug: Naltrexone 32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 32 mg plus bupropion 360 mg per day
Trial: 20673995
Drug: Naltrexone 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 16 mg plus bupropion 360 mg per day
Trial: 23726126
Drug: Multiphasic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiphasic injection protocol (protocol I) with 89 mL of Optiray 350
Trial: 23726126
Drug: Test bolus
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test bolus injection protocol (protocol II) with a 10 mL test bolus of Optiray 350 followed by 40 mL of contrast medium
Trial: 19485286
Drug: Topical cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporin A 1%
Trial: 8451895
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g Cefoxitin
Trial: 8451895
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g Cefuroxim
Trial: 20103314
Drug: Both heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both heparin groups (low-dose and high-dose)
Trial: 15961531
Drug: Control (saline;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (saline; rate 4 ml/min)
Trial: 9695210
Drug: ceftazidime 2
RxNorm normalized name: ceftazidime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ceftazidime 2 g every 8 h plus amikacin 15 mg/kg i.v. per day
Trial: 2671218
Drug: Topical Bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Bupivacaine 0.5 per cent solution
Trial: 776539
Drug: tolmetin 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolmetin 1200 mg per day
Trial: 776539
Drug: tolmetin 1400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolmetin 1400 mg daily
Trial: 776539
Drug: indomethacin 150
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: indomethacin 150 mg daily
Trial: 6634894
Drug: Hydrocortisone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (20 mg)
Trial: 31689951
Drug: Placebo (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3.5 g inert stevia)
Trial: 24235245
Drug: 15% propolis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% propolis solution
Trial: 16885888
Drug: Topical antiallergic
RxNorm normalized name: Other antiallergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antiallergic treatment (membrane stabilizer or antihistamine)
Trial: 15491434
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus plus salicylic acid
Trial: 2898227
Drug: Intracerebroventricular (ICV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracerebroventricular (ICV) cholinergic drug infusion (bethanechol chloride)
Trial: 15969668
Drug: Low-dose peanut
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose peanut challenge
Trial: 10695096
Drug: nifedipine retard
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nifedipine retard 10 mg twice daily
Trial: 6801218
Drug: Intracranial pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracranial pressure monitoring and aggressive treatment (including mannitol therapy and drainage of cerebrospinal fluid)
Trial: 6801218
Drug: ICP monitoring
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ICP monitoring with aggressive treatment
Trial: 27166670
Drug: Annual prostate‐specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual prostate‐specific antigen (PSA) screening for 6 years and digital rectal examination for 4 years
Trial: 23775532
Drug: Totally extraperitoneal
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Totally extraperitoneal patch (TEP) hernioplasty
Trial: 23775532
Drug: Open tension‐free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open tension‐free plug and patch (PP) technique
Trial: 17894706
Drug: Continuous cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous cyclosporine (CyA) therapy at individualized effective doses
Trial: 17894706
Drug: Intermittent cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent cyclosporine (CyA) therapy
Trial: 17894706
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment schedules
Trial: 15250006
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose heparin (control group)
Trial: 7677459
Drug: High-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose insulin infusion for 7 days
Trial: 31132908
Drug: Tablet and
RxNorm normalized name: TABLET AND CAPSULE, DOSE PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet and pen version
Trial: 31132908
Drug: Tablet and
RxNorm normalized name: TABLET AND CAPSULE, DOSE PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet and finger version
Trial: 27493198
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fexofenadine and ranitidine (blockade)
Trial: 26187277
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) adjunctive treatment for fractures, including Shu-jing-huo-xue-tang and Rhizoma Drynariae (Gu-sui-bu) as common prescriptions.
Trial: 20347079
Drug: Intramuscular progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular progesterone (IMP)
Trial: 7766738
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of 50 micrograms of octreotide
Trial: 2277579
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 3 mL normal saline into the P6 acupuncture point after anesthesia
Trial: 15781835
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg of levetiracetam
Trial: 9346622
Drug: Intravenous ceftazidime
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ceftazidime and flucloxacillin plus oral and enteral decontamination with colistin, tobramycin, and amphotericin B (group 1)
Trial: 1869454
Drug: Hyperfractionated RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperfractionated RT (70.4 Gy in 64 fractions of 1.1 Gy given twice a day)
Trial: 31338732
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine patches for 6 weeks
Trial: 29408562
Drug: High-intensity lifestyle
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity lifestyle intervention delivered by health coaches; 16 in-person sessions and 6 telephone sessions in the first 6 months, followed by at least monthly sessions for 18 months.
Trial: 29408562
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care provided by primary care practitioners with information on weight management and reimbursement for obesity treatment.
Trial: 27080034
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg daily on-demand
Trial: 27080034
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg daily continuously
Trial: 21900941
Drug: Aliskiren 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 75 mg
Trial: 12100802
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous meperidine
Trial: 10626032
Drug: 44 mg/24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 44 mg/24 hour nicotine patch for 4 weeks
Trial: 10626032
Drug: 22 mg/24
RxNorm normalized name: ProStep, 22 mg/24 hr transdermal film, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22 mg/24 hour nicotine patch for 6 weeks
Trial: 10626032
Drug: Behavioral intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral intervention (minimal, brief individual counseling, group therapy)
Trial: 7847611
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g ethanol/kg body weight
Trial: 7847611
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g ethanol/kg body weight
Trial: 1493666
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment (group 1)
Trial: 27033026
Drug: omega‐3 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega‐3 (4 g/day) and vitamin E (400 IU/day)
Trial: 25471216
Drug: Iron (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron (50 mg) supplementation
Trial: 25471216
Drug: Iron (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron (50 mg) + DHA (420 mg) + EPA (80 mg) supplementation
Trial: 9506873
Drug: Multimodal cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal cognitive behavioral treatment (MMCBT) for 4 weeks
Trial: 9506873
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (ordinary treatment through general practitioners)
Trial: 3290578
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy using Flutamide and LHRH agonist [D‐Trp6]LHRH ethylamide
Trial: 29778106
Drug: Topical bromfenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bromfenac 0.09% twice daily for 2 weeks
Trial: 29778106
Drug: Topical dexamethasone
RxNorm normalized name: dexamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dexamethasone 0.1% 4 times daily with tapering
Trial: 29778106
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of topical bromfenac 0.09% and dexamethasone 0.1%
Trial: 7668872
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with MMC 12 mg/m2 on the day of operation, followed by 6 mg/m2 every two months for 6 times, and FT 800 mg/body/day for one year.
Trial: 7668872
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in rectal cancer cases, specifically Dukes C cases.
Trial: 20131073
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity diode laser adjunct to root scaling and planing
Trial: 338255
Drug: feprazone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: feprazone (600 mg/day)
Trial: 338255
Drug: ibuprofen (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen (1200 mg/day)
Trial: 26431977
Drug: PACT (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PACT (100 μg mL(‐1) TBO followed by 94J cm(‐2) LED irradiation)
Trial: 23258380
Drug: Bleaching agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleaching agent
Trial: 23258380
Drug: Peroxide‐free bleaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peroxide‐free bleaching agent
Trial: 20390807
Drug: Combined parent-child/family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined parent-child/family therapy treatment
Trial: 20390807
Drug: Cognitive-behavioral individual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral individual child treatments
Trial: 20390807
Drug: Individual child
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual child treatments
Trial: 17712672
Drug: Intratympanic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratympanic treatment with AM‐111 at a concentration of 0.4 mg/ml or 2 mg/ml
Trial: 10454450
Drug: DHA (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (4 g/d)
Trial: 9665096
Drug: Corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil (4 g/d, control)
Trial: 818720
Drug: Sotalol (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (320 mg per day, 160 mg twice daily)
Trial: 23368820
Drug: Ulinastatin (150,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin (150,000 U by i.v. drip infusion for 2 hours)
Trial: 19465485
Drug: High-dose octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose octreotide (60 mg/28 days)
Trial: 8142675
Drug: Norfloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (200 mg orally, 2 or 4 times daily) + Amphotericin B (200 mg orally, 4 times daily)
Trial: 2878598
Drug: Once-daily bevantolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily bevantolol (200 mg)
Trial: 20135139
Drug: Bevacizumab administered
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab administered 20 days before vitrectomy
Trial: 15811091
Drug: 8-MOP 0.01%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-MOP 0.01% gel plus UVA
Trial: 11916547
Drug: Toxicity profile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toxicity profile of the treatment
Trial: 10216807
Drug: Eprosartan (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan (200 mg b.i.d. to 300 mg b.i.d.)
Trial: 10216807
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mg o.d. to 20 mg o.d.)
Trial: 10216806
Drug: Eprosartan +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan + Hydrochlorothiazide (HCTZ) (12.5‐25 mg o.d.)